23/09/2005 (Agence Europe) - The European Medicines Agency (EMEA) is recommending as a precautionary measure the suspension of the marking authorisation for Hexavac due to concerns about the long-term protection against Hepatitis B. Hexavac is a combined vaccine for infants and children against diphtheria, tetanus, whooping cough, Hepatitis B, polio and haemophilus influenza B. An EMEA press release explains that variability in the production process for the vaccine's Hepatitis B component...